Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin plus 10-day decitabine in unfit adult AML and high-risk MDS
2018-000047-31Phase 2Active
- Sponsor
- HOVON
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Decitabine 10-day regimen with Midostaurin plus decitabine 10-day regimen (2 arms). Primary endpoint: Cumulative CR/CRi rate during 3 cycles. Started Jan 2019; status: active.
02
Drugs
midostaurindecitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2018-000047-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000047-31.